



British Association of
Perinatal Medicine



Antenatal Optimisation for Preterm Infants less than 34 weeks

A Quality Improvement Toolkit

Aims, Evidence and Rationale

October 2020

in collaboration with

NNAP
National Neonatal
Audit Programme

Antenatal Optimisation: Toolkit Aims

- All women who are at risk of preterm birth (including both those in threatened preterm labour and those requiring intervention because of maternal or fetal indications), are **identified appropriately and in a timely manner** using evidence-based methods.
- All women giving birth before 34 weeks of gestation, should receive a full course of **antenatal steroids** no longer than 7 days prior to birth, and ideally completed 24-48 hours before birth
- All women giving birth before 30 weeks of gestation, should receive a loading dose and ideally a minimum of 4 hour infusion of **antenatal magnesium sulphate** within the 24 hours prior to birth.
- All women in established preterm labour (<37 weeks) should receive **intrapartum antibiotic prophylaxis** to prevent early onset neonatal Group B Streptococcal (GBS) infection irrespective of whether they have ruptured amniotic membranes.
- Singleton infants less than 27 weeks of gestation, multiples less than 28 weeks of gestation and any gestation with an estimated fetal weight of less than 800g should be **born in a maternity service on the same site as a neonatal intensive care unit (NICU).**

Notes:

Aims are different to standards. This toolkit does not seek to delineate standards. The aims of this toolkit are to improve the antenatal environment for all preterm infants whilst reducing unnecessary and potentially harmful treatments in those women who do not go on to give birth prematurely. It is fully acknowledged that while units and networks will strive to achieve full compliance across all measures without unnecessary intervention, due to the complex presentation of preterm labour this may not be achievable in all circumstances.

Where there is evidence of maternal or fetal compromise necessitating urgent intervention, achievement of the above objectives should never delay birth.

The optimal timing of antenatal steroids should be achieved by more accurate prediction of preterm birth rather than a routine strategy of repeat dosing which does not improve mortality but may impact fetal growth.

Birth during transport is extremely rare. In the vast majority of cases, timely transfer is appropriate and achievable, and the benefits outweigh the risks. Every decision about appropriateness of transfer should be made by a consultant obstetrician and be based on an assessment of the risk and benefit, distance to travel and risk of birth during the journey.

The delineation of strategies to prevent preterm birth is outwith the scope of this toolkit and are covered by NICE¹¹ and the UK Preterm Clinical Network¹².

Parents should be actively involved in planning the birth of their preterm baby along with neonatal, obstetric and midwifery teams. At gestations <27w, parents should be involved in risk-based shared decision-making with the most senior clinicians available in accordance with the BAPM Extreme Preterm Framework¹⁰. This working group recognises that not all families and clinicians will opt for an active treatment pathway for infants at very high risk of a poor outcome. Staff should be aware of local bereavement care arrangements and palliative care pathways and be able to signpost to local and national bereavement organisations. Clinical teams requiring support in these challenging cases should consult their local tertiary referral units for advice and guidance.

Rationale

Prematurity is the most significant cause of mortality in children under five and is associated with significant morbidity in surviving infants. Many well-established evidence-based antenatal interventions reduce the

risk of neonatal death and associated preterm morbidities. UK audit data show there is variable uptake in these interventions with wide variability between units and networks¹³. Optimal delivery of these interventions is dependent on the accurate prediction of preterm birth and the BAPM strongly recommends adoption of the QUIPP app using the [QUIPP App Toolkit](#)¹⁴ to improve prediction and timing of interventions. This toolkit seeks to provide users with a framework to understand the local context for QI, understanding enablers and barriers to implementation so that key interventions can be more reliably delivered.

A summary of the evidence and key drivers for antenatal optimisation is provided in [Appendix 3](#).


How to use this toolkit

This improvement activity referred to in this toolkit is not intended to be read as a guideline which mandates a standard improvement journey for all units. Instead it is a practical resource from which units who wish to improve compliance rates of antenatal optimisation measures can select the most suitable interventions for their particular context. For example, there are units which achieve high NNAP compliance with 'antenatal steroid administration' but this may be at the expense of optimal timing, occurring more than a week before birth with many more women treated than who go on to have a preterm birth. Another unit may have a lower compliance rate but the timing of administration is optimal. The improvement solution for each unit may be different. Similarly, optimal place of birth may be variably dictated by accuracy in predicting preterm birth or by referral, capacity or transfer issues. Individual units are encouraged to interrogate their processes in order to understand where and how optimisation measures are applied in their local setting and select interventions which are best suited to their context.

Antenatal Optimisation: Rationale and Key Elements


Antenatal Optimisation to Improve Preterm Outcomes- the rationale

See [Appendix 3](#) for full evidence summary



The Antenatal Optimisation Care Bundle- the key elements

See [Appendix 3](#) for full evidence summary



Antenatal Optimisation: Implementation evidence and resources

Table of evidence

The following table provides evidence of that which has been shown to be successful in practice in implementing the various elements of the Antenatal Optimisation pathway and lists other resources to support implementation.

Implementation strategy	Reference
Prediction of preterm birth	
Triage system for rapid assessment of women presenting in preterm labour	19
Use of clinical decision-making technology to improve accuracy	20
Guidelines for steroids, magnesium and antibiotics:	
Evidence-based	21-27
Readable, accessible and supported with training and implementation tools	21 23-29
High reliability of delivery: consistent adoption without discordant senior opinion	24-31
National or regional processes that incentivise, educate, train and support	1 23 25 27 32 33
Local, regional or national processes that support:	
Timely and efficient delivery (including standardisation, checklists, feedback, reminders, decision aids, process redundancy and default actions)	24-28
Cross disciplinary engagement and joint working	23-29 31 32 34
Clinical leadership	25 27 29
Data collection, audit and feedback	22-27 29 32 35
Training to promote benefits of interventions	24-29 31
Training in QI methodology	21 23 25 34
Change behaviour and improvements in organisational culture	21 23 25 27 28 34
Partnering with parents for improvement	26 29
Network level arrangements for:	
In utero transfer of women at risk of preterm birth	27 31 32 36
Neonatal unit capacity	27 32 36
Labour ward capacity	27 36
Centralisation of perinatal retrieval	37 38
Simplifying referral processes	27
Network level responsibility for:	
Standardising care throughout region	22 27 34 37 39-41
Reducing variation	22 27 34 39-41
Sharing performance data including exception reporting	22 27 30 34 35 39 40
Opportunities for shared learning	22 27 30 34 39 40
Organisations and resources supporting or incentivising quality improvement in Antenatal Optimisation	
Maternity and Neonatal Safety Improvement Programme, NHS England	2
Preterm Perinatal Wellbeing Package, MCQIC-SPSP	8
NNAP Online	1
Saving Babies' Lives Version 2, NHS England	4
NICE Adoption Support resource for Placental Growth Factor	42
Maternity Incentive Scheme, Clinical Negligence Scheme for Trusts, NHS Resolution	33
PReCePT	43
PERIPrem care bundle, West of England Academic Health Sciences Network	7
European Standards of Care for Newborn Health	44
Bliss Baby Charter	45

Appendix 3. Evidence Summary and Key Drivers

Prediction of Preterm Birth		
Objective: All women who are at risk of preterm birth (including both those in threatened preterm labour and those requiring to be delivered because of maternal or fetal indications), are identified appropriately and in a timely manner using evidence-based methods.		
Evidence-based interventions	Professional Recommendations	Quality Improvement Initiatives
<p>QUIPP app: Using a 5% chance of birth, predicts PTB in next 7d in women <37w and avoids 90% of admissions^{20 50}</p> <p>Quantitative fetal fibronectin (qfFN): Growing body of evidence for predictive utility across risk range Predicts PTB <30w in singleton/multiple pregnancy^{51 52} Given the linear relationship between qfFN and preterm birth a variable threshold better reflects individual patient circumstances and different treatment options (awaiting QUIDS study⁵³)</p> <p>Cervical length (CL): A meta-analysis of 28 studies reported a pooled PLR of 5.71 (3.77–8.65) and a NLR 0.51 (0.33–0.80) (69) suggesting that cervical length is a moderately useful test for PTB prediction⁵⁴. The risk of PTB changes across the range of cervical lengths and gestations.</p> <p>Combination of CL and qfFN: Addition of CL refines predictive ability of qfFN^{55 56} and may save €480 per patient⁵⁵</p> <p>Preterm birth history alone: 10-57% of pregnant women with a PTB history will give birth preterm⁵⁷</p> <p>Placental growth factor and sFlt-1/PGF ratio: Rules out pre-eclampsia within the next 7d in women with suspected pre-eclampsia <35w^{58 59}</p>	<p>NHS England, SBLCBv2⁶⁰: Diagnosis of preterm labour can be optimised by use of qfFN, cervical length and the QUIPP app.</p> <p>BAPM¹⁴: Endorsement of QUIPP app</p> <p>NICE¹¹:</p> <ul style="list-style-type: none"> • CL and qfFN for suspected preterm labour >30w gestation with CL <15mm deemed to be high risk. • Treat-all policy for those presenting below 30w <p>UK Preterm Clinical Network and the RCOG Preterm CSG^{12 61}:</p> <ul style="list-style-type: none"> • Recommend the use of cervical length, quantitative fFN and decision aids such as the QUIPP app to facilitate prediction and management of threatened preterm labour which is in line with the SBLCBv2 <p>NICE⁴²: PIGF is recommended to help rule out pre-eclampsia in women between 20 and 34+6 weeks</p>	<ul style="list-style-type: none"> • PERIPrem care bundle of the West of England AHSN⁷: use of qfFN to predict PTL • Pan London guideline for in utero transfer⁶² • NHS England Accelerated Access Programme: Placental Growth Factor for improved diagnosis of pre-eclampsia⁶³

Antenatal Steroids		
Objective: All women giving birth before 34 weeks of gestation, should receive a full course of antenatal steroids no longer than 7 days prior to birth, and ideally within 24-48 hours.		
Evidence	Professional Recommendations	Standards and Quality Improvement Initiatives
<p>Antenatal steroids:</p> <ul style="list-style-type: none"> • Single course <34w reduces risk of death and major morbidity in absence of risk to mother or fetus⁶⁴ • ANS <25w may reduce mortality by 50% and severe IVH, PVL^{65 66} <p>Optimum Timing:</p> <ul style="list-style-type: none"> • Within 7d of birth, and maximum effect on reduction of IVH and mortality if given within 48h of birth^{67 68} • Benefits of steroids plateau at 12-36h and do not exceed 7d. 51% reduction in mortality if given even 6-12h before birth⁶⁸ • Only 55-68% of women receiving steroids give birth preterm^{69 70} • Only 22% of women receive steroids at optimal time^{71 72} <p>Repeat courses:</p> <ul style="list-style-type: none"> • Reduce respiratory morbidity but do not reduce mortality and may impact fetal growth⁷³ • Number of repeat treatment courses to be limited to 3 with total dose 24-48mg⁷³ 	<p>Offer ANS to women at risk of preterm birth within the next 7d:</p> <ul style="list-style-type: none"> • WHO, NICE and RCOG^{57 72 73}: from 24-33+6w^{11 74 75} <p>Discuss the use of ANS:</p> <ul style="list-style-type: none"> • NICE¹¹: between 23+0-23+6w • BAPM¹⁰: from 22w where active resuscitation is planned • European Consensus Guideline on the Management of Respiratory Distress Syndrome⁷⁶: from when infant is considered viable • UK Preterm Clinical Network¹²: highlights importance of dosing between 1-7d <p>WHO and European Consensus Guideline on the Management of Respiratory Distress Syndrome^{74 76}:</p> <ul style="list-style-type: none"> • Single repeat course if birth does not occur within 7d and high risk of birth within the subsequent 7d 	<p>NNAP¹:</p> <ul style="list-style-type: none"> • At least 85% of mothers who give birth 23-33+6w should receive at least one dose of steroids prior to birth <ul style="list-style-type: none"> • MatNeoSIP² • NHS England Neonatal Critical Care Quality Dashboard⁷⁷ • MCQIC-SPSP in Scotland. Preterm Perinatal Wellbeing package⁸ • PERIPrem care bundle of the West of England AHSN⁷
Magnesium Sulphate		
Objective: All women giving birth before 30 weeks of gestation, should receive antenatal magnesium sulphate within the 24 hours prior to birth.		
Evidence	Professional Recommendations	Standards and Quality Improvement Initiatives
<p>Antenatal magnesium sulphate:</p> <ul style="list-style-type: none"> • Given <24h prior to birth less than 32w reduces the risk of cerebral palsy and death without risk to mother or fetus^{73 78 79} <p>Gestation <24w:</p> <ul style="list-style-type: none"> • Limited evidence for magnesium administration but similar effects seen across range of gestations⁸⁰ • Infants have highest risk of neurodevelopmental 	<p>Offer Mg to women at risk of imminent PTB:</p> <ul style="list-style-type: none"> • WHO⁷⁴: <32w • NICE¹¹ and RCOG: <30w <p>Discuss the use of Mg:</p> <ul style="list-style-type: none"> • NICE¹¹: between 23+0-23+6w • BAPM¹⁰: from 22w where active resuscitation is planned. <p>Consider the use of Mg:</p> <ul style="list-style-type: none"> • NICE¹¹: Between 30-33+6w 	<p>NNAP¹:</p> <ul style="list-style-type: none"> • At least 85% of mothers who give birth <30w should receive magnesium sulphate in the 24h prior to birth <ul style="list-style-type: none"> • MatNeoSIP² • PReCePT Quality Improvement toolkit⁴⁶ • PERIPrem care bundle of the West of England AHSN-magnesium⁴³

Antenatal Optimisation for Preterm Infants less than 34 weeks
A Quality Improvement Toolkit: Aims, Evidence and Rationale

<p>impairment¹⁰ and may be most likely to benefit</p> <ul style="list-style-type: none"> • Optimum level is at least 4h after loading dose⁸¹ 	<p>Timing:</p> <ul style="list-style-type: none"> • NICE¹¹ and UKPCN¹²: A loading dose of 4g followed by infusion of 1g/h until birth or for 24h whichever sooner 	<ul style="list-style-type: none"> • MCQIC-SPSP in Scotland. Preterm Perinatal Wellbeing package⁸
Antibiotics		
Objective: All women in established preterm labour should receive intrapartum antibiotic prophylaxis to prevent early onset neonatal Group B Streptococcal (GBS) infection irrespective of whether they have ruptured amniotic membranes.		
Evidence	Professional Recommendations	Quality Improvement Initiatives
<p>Preterm prelabour rupture of the membranes and preterm labour are associated with early onset neonatal infection with GBS⁸²</p> <p>Antibiotics given at least 4h before birth reduces the risk of GBS sepsis from 12.5% to 1.6%¹⁷</p>	<p>WHO, NICE, RCOG^{11 74 82}: Antibiotic administration is recommended in preterm prelabour rupture of membranes.</p> <p>NICE¹¹: Antibiotics can delay PTB and reduce mortality and morbidity associated with congenital infection</p> <p>NICE¹¹ and RCOG⁸²: penicillin in the context of preterm labour or GBS</p>	<p>Neither the NNAP nor the NMPA currently collect data on administration of maternal antibiotics in these contexts. We recommend that units consider undertaking audit of this intervention to ensure optimal compliance with professional recommendations.</p>
Place of Birth		
Objective: Singleton infants less than 27 weeks of gestation, multiples less than 28 weeks of gestation and infants with an estimated fetal weight of less than 800g should be born in a maternity service on the same site as a neonatal intensive care unit (NICU).		
Evidence	Professional Recommendations	Standards and Quality Improvement Initiatives
<p>Reduced risk of death of extreme preterm infants if birth occurs in a high volume, neonatal intensive care setting^{18 83-85}</p> <p>Reduction in mortality is ~50%⁸⁴</p> <p>Reduction in major morbidities of extreme preterm infants if born in a tertiary centre (NEC⁸⁶ and PVL⁸⁷)</p> <p>Being born in a non-NICU setting +/- transfer is associated with increased risks of mortality, IVH and severe brain injury in extreme preterm infants^{18 88-90}</p>	<p>BAPM¹⁰:</p> <ul style="list-style-type: none"> • In utero transfer to facilitate birth of extremely preterm infants in a tertiary centre <p>NHS England⁹¹:</p> <ul style="list-style-type: none"> • Infants <27w to be treated in high volume centres with sufficiently expert and experienced staff <p>The Scottish Maternity and Neonatal Services Review⁹²:</p> <ul style="list-style-type: none"> • Develop formal pathways to ensure that clear agreements are in place to treat the highest risk preterm babies in fewer centres, while returning babies to their local area as soon as clinically appropriate 	<p>NNAP¹: 85% of babies less than 27w should be born in a maternity service on the same site as a NICU</p> <p>The European Standards of Care for Newborn Health⁹³: Perinatal centralisation of extremely preterm infants with well-organised perinatal networks</p> <ul style="list-style-type: none"> • MatNeoSIP² • Neonatal Critical Care Quality Dashboard⁷⁷ • MCQIC-SPSP in Scotland. Preterm Perinatal Wellbeing package⁸ • PERIPrem care bundle of the West of England AHSN⁷

References

1. NNAP Online. National Neonatal Audit Programme: Royal College for Paediatrics and Child Health; [Available from: <https://nnap.rcpch.ac.uk>]
2. Maternity and Neonatal Safety Improvement Programme: NHS Improvement; [Available from: <https://improvement.nhs.uk/resources/maternal-and-neonatal-safety-collaborative/>]
3. Maternity and Children's Quality Improvement Collaborative- Scottish Patient Safety Programme [Available from: <https://ihub.scot/improvement-programmes/scottish-patient-safety-programme-spsp/maternity-and-children-quality-improvement-collaborative-mcqic/neonatal-care/>]
4. Saving Babies Lives' Version 2. A care bundle for reducing perinatal mortality: NHS England; 2019 [Available from: <https://www.england.nhs.uk/wp-content/uploads/2019/07/saving-babies-lives-care-bundle-version-two-v5.pdf>].
5. Neonatal Service Quality Indicators: Standards relating to structures and processes: British Association of Perinatal Medicine; 2017 [Available from: <https://www.bapm.org/resources/11-neonatal-service-quality-indicators-standards-relating-to-structures-and-processes-2017>].
6. Quality Improvement in Child Health Strategic Framework: Royal College of Paediatrics and Child Health [Available from: <https://www.rcpch.ac.uk/resources/quality-improvement-child-health-framework-supporting-delivery-high-quality-care>]. .
7. PERIPrem Care Bundle: West of England Academic Health Sciences Network 2020 [Available from: <https://www.weahsn.net/our-work/transforming-services-and-systems/periprem/periprem-project/>].
8. Preterm Perinatal Wellbeing Package: Maternity and Children Quality Improvement Collaborative, Scottish Patient Safety Programme. Health Improvement Scotland; [Available from: <https://ihub.scot/media/5311/20180808-preterm-web.pdf>]
9. Implementing the Recommendations of the Neonatal Critical Care Transformation Review: NHS England; 2019 [updated 2019. Available from: <https://www.england.nhs.uk/publication/implementing-the-recommendations-of-the-neonatal-critical-care-transformation-review/>].
10. Perinatal Management of Extreme Preterm Birth Before 27 weeks of Gestation. A BAPM Framework for Practice: British Association of Perinatal Medicine; 2019 [Available from: <https://www.bapm.org/resources/80-perinatal-management-of-extreme-preterm-birth-before-27-weeks-of-gestation-2019>].
11. Preterm Labour and Birth: National Institute for Clinical Excellence; 2019 [Available from: <https://www.nice.org.uk/guidance/ng25>].
12. Reducing Preterm Birth: UK Preterm Clinical Network; 2019 [Available from: <https://www.tommys.org/sites/default/files/Preterm%20birth%20guidelines.pdf>].
13. National Neonatal Audit Programme. 2019 Annual Report on 2018 Data: Royal College for Paediatrics and Child Health; 2019 [Available from: <https://www.rcpch.ac.uk/resources/national-neonatal-audit-programme-annual-report-2019>]
14. QUIPP App Toolkit: British Association of Perinatal Medicine; 2020 [Available from: <https://www.bapm.org/pages/187-quipp-app-toolkit>].
15. Travers CP, Clark RH, Spitzer AR, et al. Exposure to any antenatal corticosteroids and outcomes in preterm infants by gestational age: prospective cohort study. *BMJ* 2017;356:j1039. doi: 10.1136/bmj.j1039
16. Crowther C. Personal Communication. Magnesium: NNT <30 weeks, 2018.

17. Fairlie T, Zell ER, Schrag S. Effectiveness of intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal disease. *Obstet Gynecol* 2013;121(3):570-7. doi: 10.1097/AOG.0b013e318280d4f6 [published Online First: 2013/05/03]
18. Helenius K, Longford N, Lehtonen L, et al. Association of early postnatal transfer and birth outside a tertiary hospital with mortality and severe brain injury in extremely preterm infants: observational cohort study with propensity score matching. *BMJ* 2019;367:l5678. doi: 10.1136/bmj.l5678
19. Kenyon S, Hewison A, Dann SA, et al. The design and implementation of an obstetric triage system for unscheduled pregnancy related attendances: a mixed methods evaluation. *BMC Pregnancy Childbirth* 2017;17(1):309. doi: 10.1186/s12884-017-1503-5 [published Online First: 2017/09/20]
20. Watson HA, Carlisle N, Kuhrt K, et al. EQUIPTT: The Evaluation of the QUIPP app for Triage and Transfer protocol for a cluster randomised trial to evaluate the impact of the QUIPP app on inappropriate management for threatened preterm labour. *BMC Pregnancy and Childbirth* 2019;19(1):68. doi: 10.1186/s12884-019-2210-1
21. Liu G SJ, Gülmezoglu A, et al. Antenatal corticosteroids for management of preterm birth: a multi-country analysis of health system bottlenecks and potential solutions. *BMC Pregnancy Childbirth* 2015;15:S3. doi: 10.1186/1471-2393-15-S2-S3
22. Lee HC, Lyndon A, Blumenfeld YJ, et al. Antenatal Steroid Administration for Premature Neonates in California. *Obstetrics & Gynecology* 2011;117(3):603-09. doi: 10.1097/AOG.0b013e31820c3c9b
23. Lee SK, Beltempo M, McMillan DD, et al. Outcomes and care practices for preterm infants born at less than 33 weeks' gestation: a quality-improvement study. *Canadian Medical Association Journal* 2020;192(4):E81-E91. doi: 10.1503/cmaj.190940
24. Chaillet N, Dubé E, Dugas M, et al. Evidence-Based Strategies for Implementing Guidelines in Obstetrics: A Systematic Review. *Obstetrics & Gynecology* 2006;108(5):1234-45. doi: 10.1097/01.AOG.0000236434.74160.8b
25. Burhouse A, Lea C, Ray S, et al. Preventing cerebral palsy in preterm labour: a multiorganisational quality improvement approach to the adoption and spread of magnesium sulphate for neuroprotection. *BMJ Open Quality* 2017;6(2):e000189. doi: 10.1136/bmjopen-2017-000189
26. Antenatal Corticosteroids Project: Ohio Perinatal Quality Collaborative; [Available from: <https://www.opqc.net/projects/OB-ANCS>]
27. Edwards K, Impey L. Extreme preterm birth in the right place: a quality improvement project. *Archives of Disease in Childhood - Fetal and Neonatal Edition* 2020;105(4):445-48. doi: 10.1136/archdischild-2019-317741
28. Mc Goldrick EL, Crawford T, Brown JA, et al. Identifying the barriers and enablers in the implementation of the New Zealand and Australian Antenatal Corticosteroid Clinical Practice Guidelines. *BMC Health Services Research* 2016;16(1):617. doi: 10.1186/s12913-016-1858-8
29. Narayanan S KA, Shetty N, Coker M. Case Study: NNAP – improving magnesium sulphate uptake. In: Programme NNA, ed. NNAP Case Studies. <https://www.rcpch.ac.uk/resources/think-magnesium-multidisciplinary-approach-improve-magnesium-sulphate-uptake-case-study>, 2018.
30. Lee SK, Shah PS, Singhal N, et al. Association of a quality improvement program with neonatal outcomes in extremely preterm infants: a prospective cohort study. *Canadian Medical Association Journal* 2014;186(13):E485-E94. doi: 10.1503/cmaj.140399
31. Binder S, Hill K, Meinzen-Derr J, et al. Increasing VLBW Deliveries at Subspecialty Perinatal Centers via Perinatal Outreach. *Pediatrics* 2011;127(3):487-93. doi: 10.1542/peds.2010-1064
32. Langham E ND, East of England Neonatal Operational Delivery Network (ODN). Improving the rate of babies born at less than 27 weeks gestation in a maternity unit with a NICU on site. In: RCPCH, ed. RCPCH QI Central.

<https://www.qicentral.org.uk/safety/safety-culture/improving-rate-babies-born-less-27-weeks-gestation-maternity-unit-nicu-site>.

33. Maternity Incentive Scheme, Clinical Negligence Scheme for Trusts, NHS Resolution [Available from: <https://resolution.nhs.uk/wp-content/uploads/2020/02/Maternity-incentive-scheme-year-three-changes-to-safety-actions.pdf>].
34. De Silva DA, Synnes AR, von Dadelszen P, et al. MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)—implementation of a national guideline in Canada. *Implementation Science* 2018;13(1):8. doi: 10.1186/s13012-017-0702-9
35. Smith J, Gupta S, Williams E, et al. Providing antenatal corticosteroids for preterm birth: a quality improvement initiative in Cambodia and the Philippines. *International Journal for Quality in Health Care* 2017;28(6):682-88. doi: 10.1093/intqhc/mzw095
36. Munthali K, Harrison C. The continuing impact of capacity on a region's in utero transfer requests. *Acta Paediatr* 2020;109(6):1148-53. doi: 10.1111/apa.15070 [published Online First: 2019/10/21]
37. Helenius K, Gissler M, Lehtonen L. Trends in centralization of very preterm deliveries and neonatal survival in Finland in 1987-2017. *Transl Pediatr* 2019;8(3):227-32. doi: 10.21037/tp.2019.07.05 [published Online First: 2019/08/16]
38. Lui K, Abdel-Latif ME, Allgood CL, et al. Improved Outcomes of Extremely Premature Outborn Infants: Effects of Strategic Changes in Perinatal and Retrieval Services. *Pediatrics* 2006;118(5):2076-83. doi: 10.1542/peds.2006-1540
39. Wirtschafter DD, Danielsen BH, Main EK, et al. Promoting antenatal steroid use for fetal maturation: Results from the California Perinatal Quality Care Collaborative. *The Journal of Pediatrics* 2006;148(5):606-12.e1. doi: 10.1016/j.jpeds.2005.12.058
40. Profit J, Goldstein BA, Tamaresis J, et al. Regional Variation in Antenatal Corticosteroid Use: A Network-Level Quality Improvement Study. *Pediatrics* 2015;135(2):e397-e404. doi: 10.1542/peds.2014-2177
41. Kaplan HC, Sherman SN, Cleveland C, et al. Reliable implementation of evidence: a qualitative study of antenatal corticosteroid administration in Ohio hospitals. *BMJ Quality & Safety* 2016;25(3):173-81. doi: 10.1136/bmjqs-2015-003984
42. PIGF-Based Testing To Help Diagnose Suspected Pre-Eclampsia: National Institute for Health and Care Excellence; May 2016 [Available from: <https://www.nice.org.uk/guidance/dg23/resources/adoption-support-resource--insights-from-the-nhs-2612229232/chapter/1-Introduction>]
43. PERIPrem Care Bundle: Antenatal magnesium sulphate 2020 [Available from: <https://www.weahsn.net/our-work/transforming-services-and-systems/periprem/periprem-bundle-antenatal-magnesium-sulphate/>].
44. European Standards of Care for Newborn Health: EFCNI, Cetin I, Schlembach D et al; 2018 [Available from: <https://newborn-health-standards.org/maternal-transfer/>]
45. Bliss Baby Charter: Bliss; 2015 [Available from: <https://www.bliss.org.uk/health-professionals/bliss-baby-charter>].
46. PRaCePT Resources: PRaCePT Programme. The AHSN Network; [Available from: <http://www.ahsnnetwork.com/about-academic-health-science-networks/national-programmes-priorities/precept/precept-resources>].
47. BSOTS: Birmingham Symptom Specific Obstetric Triage System Training Manual: Birmingham Women's and Children's NHS Foundation Trust and University of Birmingham; 2018 [Available from: https://www.wmahsn.org/storage/resources/documents/FULL_Training_Version_30052019ej.pdf].

48. Situation Awareness for Everyone (S.A.F.E) toolkit: Royal College for Paediatrics and Child Health; [Available from: <https://www.rcpch.ac.uk/resources/situation-awareness-everyone-safe-toolkit-introduction>].
49. Perinatal Teamworking. The PReCePT2 Study.: The Health Foundation; [Available from: <https://www.health.org.uk/improvement-projects/precept2-reducing-brain-injury-through-improving-uptake-of-magnesium-sulphate>].
50. Watson HA, Carter J, Seed PT, et al. The QUIPP App: a safe alternative to a treat-all strategy for threatened preterm labor. *Ultrasound in Obstetrics & Gynecology* 2017;50(3):342-46. doi: 10.1002/uog.17499
51. Abbott DS, Hezelgrave NL, Seed PT, et al. Quantitative fetal fibronectin to predict preterm birth in asymptomatic women at high risk. *Obstet Gynecol* 2015;125(5):1168-76. doi: 10.1097/aog.0000000000000754 [published Online First: 2015/05/02]
52. Kuhrt K, Hezelgrave-Elliott N, Stock SJ, et al. Quantitative fetal fibronectin for prediction of preterm birth in asymptomatic twin pregnancy. *Acta Obstet Gynecol Scand* 2020 doi: 10.1111/aogs.13861 [published Online First: 2020/04/07]
53. Stock SJ, Wotherspoon LM, Boyd KA, et al. Quantitative fibronectin to help decision-making in women with symptoms of preterm labour (QUIDS) part 1: Individual participant data meta-analysis and health economic analysis. *BMJ Open* 2018;8(4):e020796. doi: 10.1136/bmjopen-2017-020796
54. Sotiriadis A, Papatheodorou S, Kavvadias A, et al. Transvaginal cervical length measurement for prediction of preterm birth in women with threatened preterm labor: a meta-analysis. *Ultrasound Obstet Gynecol* 2010;35(1):54-64. doi: 10.1002/uog.7457 [published Online First: 2009/12/17]
55. van Baaren GJ, Vis JY, Grobman WA, et al. Cost-effectiveness analysis of cervical length measurement and fibronectin testing in women with threatened preterm labor. *Am J Obstet Gynecol* 2013;209(5):436.e1-8. doi: 10.1016/j.ajog.2013.06.029 [published Online First: 2013/06/25]
56. Bruijn MM, Kamphuis EI, Hoesli IM, et al. The predictive value of quantitative fibronectin testing in combination with cervical length measurement in symptomatic women. *Am J Obstet Gynecol* 2016;215(6):793.e1-93.e8. doi: 10.1016/j.ajog.2016.08.012 [published Online First: 2016/08/21]
57. Kazemier BM, Buijs PE, Mignini L, et al. Impact of obstetric history on the risk of spontaneous preterm birth in singleton and multiple pregnancies: a systematic review. *Bjog* 2014;121(10):1197-208; discussion 209. doi: 10.1111/1471-0528.12896 [published Online First: 2014/06/06]
58. Cerdeira AS, O'Sullivan J, Ohuma EO, et al. Randomized Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia: INSPIRE. *Hypertension* 2019;74(4):983-90. doi: 10.1161/hypertensionaha.119.12739 [published Online First: 2019/08/14]
59. Duhig KE, Myers J, Seed PT, et al. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. *The Lancet* 2019;393(10183):1807-18. doi: 10.1016/S0140-6736(18)33212-4
60. Saving Babies' Lives Care Bundle Version 2: COVID-19 information. Appendix I: Implications of COVID-19 on reducing preterm births: NHS England, 2020.
61. Simpson N, Morris K. Personal Communication. Predicting preterm birth. On behalf of the UK Preterm Clinical Network and the RCOG CSG, 2020.
62. Pan-London guideline for in utero transfer: London Maternity Clinical Network and London Neonatal Operational Delivery Network, 2018.

63. NHS England Innovation and Technology Programme: National rollout of Placental Growth Factor testing to improve diagnosis of pre-eclampsia NHS England; 2019 [Available from: <https://www.england.nhs.uk/aac/what-we-do/how-can-the-aac-help-me/pathway-transformation-fund/>].
64. Roberts D, Brown J, Medley N, et al. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev* 2017;3(3):Cd004454. doi: 10.1002/14651858.CD004454.pub3 [published Online First: 2017/03/23]
65. Park CK, Isayama T, McDonald SD. Antenatal Corticosteroid Therapy Before 24 Weeks of Gestation: A Systematic Review and Meta-analysis. *Obstet Gynecol* 2016;127(4):715-25. doi: 10.1097/aog.0000000000001355 [published Online First: 2016/03/10]
66. Deshmukh M, Patole S. Antenatal corticosteroids for neonates born before 25 Weeks-A systematic review and meta-analysis. *PLoS One* 2017;12(5):e0176090. doi: 10.1371/journal.pone.0176090 [published Online First: 2017/05/10]
67. Norberg H, Kowalski J, Maršál K, et al. Timing of antenatal corticosteroid administration and survival in extremely preterm infants: a national population-based cohort study. *BJOG: An International Journal of Obstetrics & Gynaecology* 2017;124(10):1567-74. doi: 10.1111/1471-0528.14545
68. Norman M, Piedvache A, Børch K, et al. Association of Short Antenatal Corticosteroid Administration-to-Birth Intervals With Survival and Morbidity Among Very Preterm Infants: Results From the EPICE Cohort. *JAMA Pediatr* 2017;171(7):678-86. doi: 10.1001/jamapediatrics.2017.0602 [published Online First: 2017/05/16]
69. Rääkkönen K, Gissler M, Kajantie E. Associations Between Maternal Antenatal Corticosteroid Treatment and Mental and Behavioral Disorders in Children. *Jama* 2020;323(19):1924-33. doi: 10.1001/jama.2020.3937 [published Online First: 2020/05/20]
70. Asztalos E, Willan A, Murphy K, et al. Association between gestational age at birth, antenatal corticosteroids, and outcomes at 5 years: multiple courses of antenatal corticosteroids for preterm birth study at 5 years of age (MACS-5). *BMC Pregnancy Childbirth* 2014;14:272. doi: 10.1186/1471-2393-14-272 [published Online First: 2014/08/16]
71. Wong TTC, Tung JSZ, Lau HCQ, et al. Antenatal corticosteroids administration: are we giving them at the right time? *Arch Gynecol Obstet* 2018;297(2):373-79. doi: 10.1007/s00404-017-4577-4 [published Online First: 2017/10/31]
72. Makhija NK, Tronnes AA, Dunlap BS, et al. Antenatal corticosteroid timing: accuracy after the introduction of a rescue course protocol. *Am J Obstet Gynecol* 2016;214(1):120.e1-6. doi: 10.1016/j.ajog.2015.08.018 [published Online First: 2015/08/19]
73. Crowther CA, Middleton PF, Voysey M, et al. Effects of repeat prenatal corticosteroids given to women at risk of preterm birth: An individual participant data meta-analysis. *PLOS Medicine* 2019;16(4):e1002771. doi: 10.1371/journal.pmed.1002771
74. WHO recommendations on interventions to improve preterm birth outcomes France: World Health Organisation; 2015 [Available from: https://apps.who.int/iris/bitstream/handle/10665/183037/9789241508988_eng.pdf;jsessionid=966E028B4E46B3A246043A64E83F85EC?sequence=1].
75. Care of Women Presenting with Suspected Preterm Prelabour Rupture of Membranes from 24+0 Weeks of Gestation (Green-top Guideline No. 73): Royal College of Obstetricians & Gynaecologists; 2019 [Available from: <https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg73/>].
76. Sweet DG, Carnielli V, Greisen G, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome – 2019 Update. *Neonatology* 2019;115(4):432-50. doi: 10.1159/000499361

77. Neonatal Critical Care Quality Dashboard: NHS England; 2019/20 [Available from: <https://www.england.nhs.uk/wp-content/uploads/2019/03/nicu-metric-definitions-19-20.pdf>].
78. Doyle LW, Crowther CA, Middleton P, et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. *Cochrane Database Syst Rev* 2009(1):Cd004661. doi: 10.1002/14651858.CD004661.pub3 [published Online First: 2009/01/23]
79. Shepherd E, Salam R, Manhas D, et al. Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-analysis. *PLOS Medicine* 2019;16(12):e1002988. doi: 10.1371/journal.pmed.1002988
80. Crowther CA, Middleton PF, Voysey M, et al. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis. *PLOS Medicine* 2017;14(10):e1002398. doi: 10.1371/journal.pmed.1002398
81. Brookfield K, Su F, Elkomy M, et al. Pharmacokinetics and Placental Transfer of Magnesium Sulfate in Pregnant Women. *American Journal of Obstetrics and Gynecology* 2016;214 doi: 10.1016/j.ajog.2015.12.060
82. Group B Streptococcal Disease, Early-onset (Green-top Guideline No. 36): Royal College of Obstetricians & Gynaecologists; 2017 [Available from: <https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg36/>].
83. Lasswell SM, Barfield WD, Rochat RW, et al. Perinatal regionalization for very low-birth-weight and very preterm infants: a meta-analysis. *Jama* 2010;304(9):992-1000. doi: 10.1001/jama.2010.1226 [published Online First: 2010/09/03]
84. Watson SI, Arulampalam W, Petrou S, et al. The effects of designation and volume of neonatal care on mortality and morbidity outcomes of very preterm infants in England: retrospective population-based cohort study. *BMJ Open* 2014;4(7):e004856. doi: 10.1136/bmjopen-2014-004856
85. Shah KP, deRegnier RO, Grobman WA, et al. Neonatal Mortality After Interhospital Transfer of Pregnant Women for Imminent Very Preterm Birth in Illinois. *JAMA Pediatr* 2020;174(4):358-65. doi: 10.1001/jamapediatrics.2019.6055 [published Online First: 2020/02/18]
86. Jensen EA, Lorch SA. Effects of a Birth Hospital's Neonatal Intensive Care Unit Level and Annual Volume of Very Low-Birth-Weight Infant Deliveries on Morbidity and Mortality. *JAMA Pediatr* 2015;169(8):e151906. doi: 10.1001/jamapediatrics.2015.1906 [published Online First: 2015/08/04]
87. Boland RA, Davis PG, Dawson JA, et al. Outcomes of infants born at 22-27 weeks' gestation in Victoria according to outborn/inborn birth status. *Arch Dis Child Fetal Neonatal Ed* 2017;102(2):F153-f61. doi: 10.1136/archdischild-2015-310313 [published Online First: 2016/08/18]
88. Mohamed MA, Aly H. Transport of premature infants is associated with increased risk for intraventricular haemorrhage. *Arch Dis Child Fetal Neonatal Ed* 2010;95(6):F403-7. doi: 10.1136/adc.2010.183236 [published Online First: 2010/06/30]
89. Sasaki Y, Ishikawa K, Yokoi A, et al. Short- and Long-Term Outcomes of Extremely Preterm Infants in Japan According to Outborn/Inborn Birth Status. *Pediatr Crit Care Med* 2019;20(10):963-69. doi: 10.1097/pcc.0000000000002037 [published Online First: 2019/06/25]
90. Redpath S, Shah PS, Moore GP, et al. Do transport factors increase the risk of severe brain injury in outborn infants <33 weeks gestational age? *J Perinatol* 2020;40(3):385-93. doi: 10.1038/s41372-019-0447-1 [published Online First: 2019/08/21]
91. Implementing Better Births. Resource Pack for Maternity Systems: NHS England; 2017 [Available from: <https://www.england.nhs.uk/publication/local-maternity-systems-resource-pack/>].

92. The best start: a five-year forward plan for maternity and neonatal care in Scotland: Scottish Government; 2017 [Available from: <https://www.gov.scot/publications/best-start-five-year-forward-plan-maternity-neonatal-care-scotland>]

93. European Standards of Care for Newborn Health: Maternal transfer for specialist care: EFCNI, Cetin I, Schlembach D et al; 2018 [Available from: <https://newborn-health-standards.org/maternal-transfer/>]